HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease.

AuthorsAngelo Michele Carella, Samantha Biasco, Sandro Nati, Angela Congiu, Enrica Lerma
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 48 Issue 3 Pg. 623-4 (Mar 2007) ISSN: 1042-8194 [Print] United States
PMID17454609 (Publication Type: Case Reports, Letter)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Immunosuppressive Agents
  • Steroids
  • Rituximab
Topics
  • Adult
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents (therapeutic use)
  • Chronic Disease
  • Graft vs Host Disease (drug therapy, prevention & control)
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Lymphoma, B-Cell (drug therapy)
  • Male
  • Rituximab
  • Steroids (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: